| Gloucester Pharmaceuticals Announces Podium Presentation of Positive Results from Phase 2b Registration Trial of Romidepsin in Refractory CTCL
|
(Gloucester Pharmaceuticals)
|
05-Jun-2008 |
| Gloucester Pharmaceuticals Announces Presentation of Romidepsin Phase 1 Data in Multiple Solid Tumors at ASCO
|
(Gloucester Pharmaceuticals)
|
02-Jun-2008 |
| Gloucester Pharmaceuticals Announces Positive Results from Phase 2b Registration Trial of Romidepsin in Refractory CTCL
|
(Gloucester Pharmaceuticals)
|
19-May-2008 |
| Astellas Receives an Approvable Letter for an Immunosuppressant FK506 Modified Release Formulation in the U.S.
|
(Astellas Pharma)
|
07-May-2008 |
| Mycamine® Has Now Been Approved in Europe
|
(Astellas Pharma)
|
07-May-2008 |
| CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
|
(CV Therapeutics)
|
10-Apr-2008 |
| CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
|
(Astellas Pharma)
|
10-Apr-2008 |
| Landmark Trial ONTARGET® Proves Telmisartan is as Protective as Ramipril and Better Tolerated in a Broad High-risk Cardiovascular Population
|
(Boehringer Ingelheim)
|
31-Mar-2008 |
| Circulation Publishes Data Showing KYNAPID™ (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
|
(Cardiome Pharma)
|
25-Mar-2008 |
| Circulation Publishes Data Showing Kynapid™ (Vernakalant Hydrochloride) Injection Rapidly Converted Short-duration Atrial Fibrillation to Sinus Rhythm
|
(Astellas Pharma)
|
25-Mar-2008 |
| CV Therapeutics 8-K: Regadenoson PDUFA Action Date
|
(CV Therapeutics)
|
14-Mar-2008 |
| Astellas Receives an Approvable Letter for Their Immunosuppressant FK506 Modified Release Formulation in the U.S.
|
(Astellas Pharma)
|
14-Mar-2008 |
| Theravance Receives Additional Information Regarding FDA Cancellation of Advisory Committee Meeting
|
(Theravance)
|
03-Mar-2008 |
| FDA Approves Additional Indication for Astellas’ Mycamine®
|
(Astellas Pharma)
|
22-Jan-2008 |
| Cardiome and Astellas Announce Regulatory Update
|
(Cardiome Pharma)
|
21-Jan-2008 |
| Cardiome and Astellas Announce Regulatory Update
|
(Astellas Pharma)
|
21-Jan-2008 |
| Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
|
(Cephalon)
|
31-Dec-2007 |
| Theravance Receives Notice of Possible Telavancin Review by FDA Advisory Committee
|
(Theravance)
|
27-Dec-2007 |
| Announcement of the Launch of the Pulmonary Arterial Hypertension Agent Careload® LA Tablets 60µg in Japan
|
(Toray Industries)
|
18-Dec-2007 |
| Announcement of the Launch of the Pulmonary Arterial Hypertension Agent Careload® LA Tablets 60µg in Japan
|
(Astellas Pharma)
|
18-Dec-2007 |
| FDA Advisory Committee Recommends Approval of KYNAPID™ for Acute Atrial Fibrillation
|
(Cardiome Pharma)
|
11-Dec-2007 |
| FDA Advisory Committee Recommends Approval of KYNAPID™ for Acute Atrial Fibrillation
|
(Astellas Pharma)
|
11-Dec-2007 |
| TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
|
(Cephalon)
|
10-Dec-2007 |
| TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
|
(Cephalon)
|
10-Dec-2007 |
| Gloucester Pharmaceuticals Reports Clinically Significant Responses in Pivotal Trial of Romidepsin for Cutaneous T-Cell Lymphoma at the 2007 American Society of Hematology (ASH) Annual Meeting
|
(Gloucester Pharmaceuticals)
|
10-Dec-2007 |
| Gloucester Pharmaceuticals Announces Positive Interim Results of Phase I/II Study in Patients with Multiple Myeloma at the 2007 American Society of Hematology (ASH) Annual Meeting
|
(Gloucester Pharmaceuticals)
|
10-Dec-2007 |
| Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-Acquired Pneumonia Program
|
(Theravance)
|
05-Dec-2007 |
| TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
|
(Cephalon)
|
03-Dec-2007 |
| Cardiome Updates Guidance
|
(Cardiome Pharma)
|
26-Nov-2007 |
| Cardiome causes palpitations with trial delays
|
(Cardiome Pharma)
|
26-Nov-2007 |
| Ranbaxy Launches Ran®-Tamsulosin Hydrochloride Capsules in Canada
|
(Ranbaxy Laboratories)
|
21-Nov-2007 |
| SNDA for a Fast-acting Postprandial Hypoglicemic Agent FASTIC® Tablet / STARSIS® Tablet for Combination Therapy With Biguanide Was Approved
|
(Astellas Pharma)
|
14-Nov-2007 |
| FibroGen Announces New Research in HIF and CTGF Therapeutic Programs Presented at the Annual Meeting of the American Society of Nephrology
|
(FibroGen)
|
08-Nov-2007 |
| FibroGen Announces New Research in HIF and CTGF Therapeutic Programs Presented at the Annual Meeting of the American Society of Nephrology
|
(FibroGen)
|
07-Nov-2007 |
| Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
|
(Astellas Pharma)
|
07-Nov-2007 |
| Study Shows VAPRISOL® is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
|
(Astellas Pharma)
|
25-Oct-2007 |
| Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma
|
(Cephalon)
|
23-Oct-2007 |
| Theravance Receives FDA Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
|
(Theravance)
|
22-Oct-2007 |
| Announcement of the Acquisition of Marketing Approval for the Pulmonary Arterial Hypertension Agent Careload® LA Tablets 60µg in Japan
|
(Astellas Pharma)
|
22-Oct-2007 |
| Announcement of the Acquisition of Marketing Approval for the Pulmonary Arterial Hypertension Agent Careload® LA Tablets 60µg in Japan
|
(Toray Industries)
|
22-Oct-2007 |
| Theravance Receives FDA Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
|
(Astellas Pharma)
|
22-Oct-2007 |
| Data Show Vaprisol® is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
|
(Astellas Pharma)
|
10-Oct-2007 |
| Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm In Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
|
(Astellas Pharma)
|
10-Oct-2007 |
| Announcement of the Launch of Geninax® Tablet, an Oral New-Type Quinolone Antibacterial Agent, in Japan
|
(Astellas Pharma)
|
04-Oct-2007 |
| Announcement of the Launch of Geninax® Tablet, an Oral New-Type Quinolone Antibacterial Agent, in Japan
|
(Toyama Chemical)
|
04-Oct-2007 |
| Announcement of the Launch of Geninax(R) Tablet, an Oral New-Type Quinolone Antibacterial Agent, in Japan
|
(Taisho Pharmaceutical)
|
04-Oct-2007 |
| Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
|
(Cephalon)
|
21-Sep-2007 |
| Study Shows Vasopressin Receptor Antagonist VAPRISOL® (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
|
(Astellas Pharma)
|
20-Sep-2007 |
| Astellas Submitted a Response to the FDA Action Letter for FK506 Modified Release Formulation for Kidney Transplantation
|
(Astellas Pharma)
|
19-Sep-2007 |
| Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
|
(Theravance)
|
18-Sep-2007 |
| Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
|
(Astellas Pharma)
|
18-Sep-2007 |
| New Data from Large Safety Analysis of Mycamine Shows Favorable Clinical Safety Profile(1)
|
(Astellas Pharma)
|
18-Sep-2007 |
| Astellas Announces the Extension of US Regulatory Review for the sNDA of MYCAMINE®
|
(Astellas Pharma)
|
03-Sep-2007 |
| MediGene: European Approval Procedure for the Six-Months Dosage of Cancer Drug Eligard® Successfully Completed
|
(MediGene)
|
31-Aug-2007 |
| Eligard(R) Six-month Formulation Successfully Completes European Approval Procedure
|
(QLT)
|
31-Aug-2007 |
| Cardiome and Astellas Announce Regulatory Extension
|
(Cardiome Pharma)
|
30-Aug-2007 |
| Cardiome and Astellas Announce Regulatory Extension
|
(Astellas Pharma)
|
30-Aug-2007 |
| FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
|
(Cephalon)
|
29-Aug-2007 |
| Announcement of the Acquisition of Marketing Approval for Geninax® Tablet, an Oral New-Type Quinolone Antibiotic Agent, in Japan
|
(Toyama Chemical)
|
03-Aug-2007 |
| Theravance Announces Positive Results from Phase 2 Clinical Study with Investigational Antibiotic in Patients with Complicated Skin and Skin Structure Infections
|
(Theravance)
|
09-Jul-2007 |
| Cephalon Announces Plans for New NDA Filing for TREANDA(R)
|
(Cephalon)
|
28-Jun-2007 |
| Ranbaxy Receives Tentative Approval from US FDA for Tamsulosin Capsules
|
(Ranbaxy Laboratories)
|
22-Jun-2007 |
| Theravance Announces Enrollment of Last Patient in Phase 3 Hospital-Acquired Pneumonia Clinical Program with Investigational Antibiotic, Telavancin
|
(Theravance)
|
20-Jun-2007 |
| Astellas Announces the Launch of Advagraf® in the UK and Germany
|
(Astellas Pharma)
|
18-Jun-2007 |
| More Than Half of Hypertensive Patients Remain Uncontrolled and Thus at Higher Risk of Heart Attack and Stroke - Telmisartan May Decrease This Risk
|
(Boehringer Ingelheim)
|
18-Jun-2007 |
| New Study Shows That Telmisartan Has Greater Renoprotective Potential Than Losartan in Hypertensive Patients With Type 2 Diabetes
|
(Boehringer Ingelheim)
|
18-Jun-2007 |
| Announcement of the Launch of the Selective COX-2 Inhibitor Celecox® Tablets in Japan
|
(Astellas Pharma)
|
11-Jun-2007 |
